Paul R. Ingram

Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance

Patrick N. A. Harris, Paul Anantharajah Tambyah, David Chien Lye et al. · JAMA · 2018 · 731 citations · Full text

Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy

Paul R. Ingram, David Chien Lye, Paul Anantharajah Tambyah et al. · Journal of Antimicrobial Chemotherapy · 2008 · 163 citations · Full text

Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study

Andrew Henderson, David L. Paterson, Mark D. Chatfield et al. · Clinical Infectious Diseases · 2020 · 147 citations · Full text

Development of Colorimetric Microtiter Plate Assay for Assessment of Antimicrobials against <i>Acanthamoeba</i>

James McBride, Paul R. Ingram, Fiona L. Henriquez et al. · Journal of Clinical Microbiology · 2005 · 125 citations · Full text

Antimicrobial Chemotherapy, Bacterial Pathogens, Drug Resistance +16

Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection

Paul R. Ingram, Tim Inglis, David Moxon et al. · Intensive Care Medicine · 2010 · 100 citations · Full text

Pathogenesis, Immunology, Influenza Vaccine +3